US Drug Recall Register
Class I · High risk Completed Initiated Nov 17, 2021 (5 years ago)

Enoxaparin Sodium Injection

Class I — High risk. Reasonable probability of serious harm or death.

Why it was recalled

Temperature Abuse; temperature excursion during shipping

What was recalled

Enoxaparin Sodium Injection, USP, 40 mg/0.4 mL, Single-Dose Syringes with Automatic Safety Device, For Subcutaneous Injection, Rx Only; 0.4 mL Syringes, Manufactured for Sandoz Inc., Princeton, NJ 08540, NDC 00781-3246-02; Carton (10 x 0.4 mL Syringes), Manufactured by Shenzhen Techdow Pharmaceutical Co., Ltd. Shenzhen City, Guangdong Province 518057, China for Sandoz Inc., Princeton, NJ 08540, NDC 00781-3246-64

Recalling firm
Sandoz Inc
NDC code
00781-3246-02
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0286-2022

What should you do? A recall doesn't always mean your specific bottle is affected - it often applies to certain lots only. Check the lot number on your package against the FDA notice, and talk to your pharmacist before stopping any medication.

Other Enoxaparin recalls

See all
Class II · Moderate risk Ongoing

Enoxaparin Sodium Injection

Reason Correct Labeled Product Mispack: Bags labeled for Enoxaparin Sodium Injection, 80 mg/0.8 mL, contained Enoxaparin Sodium Injection, 30 mg/0.3 mL

Cardinal Health Inc. NDC 55154-3543-5 D-0597-2025
Class II · Moderate risk Terminated

Enoxaparin Sodium Injection

Reason CGMP Deviations: Products were exposed to temperatures outside of the products labeled storage conditions.

Cardinal Healthcare D-0179-2024
Class II · Moderate risk Terminated

Enoxaparin Dofium Injrvyion

Reason CGMP Deviations: Intermittent exposure to temperature excursion during storage.

Cardinal Health Inc. D-0426-2021
Class I · High risk Ongoing

Enoxaparin Sodium Injection

Reason Labeling; Label Mixup; syringe barrels may contain markings for 100 mg/mL (corresponding to 100 mg/mL strength) instead of 150 mg/mL (corresponding to 120 mg/0.8mL strength)

Apotex Corp. NDC 60505-0796-4 D-0262-2021
Class I · High risk Ongoing

Enoxaparin Sodium Injection

Reason Labeling; Label Mixup; syringe barrels may containing markings for 150 mg/mL (corresponding to 120 mg/0.8mL strength) instead of 100 mg/mL markings (corresponding to 100 mg/mL strength)

Apotex Corp. NDC 60505-0795-4 D-0261-2021